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Abstract: 
[1,2,3]Triazolo[1,5-a]pyridine and 3-substituted derivatives were regioselectively metalated at the 7 
position using either Bu3MgLi or (TMP)3CdLi, the former at –10 °C and the latter at room temperature. 
The lithium arylmagnesates (R = H, Me, Ph) proved to react with iodine (34-75%) or 3,4,5-
trimethoxybenzaldehyde (32-51%). Attempts to obtain the cross-couplings products using 2-
bromopyridine under palladium catalysis failed, a result attributed to the low stability of these 
compounds. The corresponding lithium arylzincates reacted in 17 to 60% yield under the same reaction 
conditions. The lithium arylcadmates were either trapped with iodine (38-76%, R = H, Me, Ph, CN, 2-
thienyl) or involved in palladium-catalyzed cross-coupling reactions with 2-bromopyridine (26-67%, R 
= H, Me, Ph). For R = 2-pyridyl, 3-(6-iodo-2-pyridyl)-[1,2,3]triazolo[1,5-a]pyridine was isolated in 
73% yield. (TMP)3CdLi also proved suitable for the clean dideprotonation of two substrates (R = H, 2-
thienyl), a result demonstrated by quenching with iodine (66-75%). 
___________________________________________________________________________________ 
Introduction 
The deprotonative metalation of aromatic rings has been widely used as a powerful method for 
regioselective functionalization. The methodology using alkyllithiums and lithium dialkylamides have 
been largely employed for this purpose.1 Nevertheless their use is limited to substrates with C-H acidity 
enhanced by directing groups and generally requires low reaction temperatures due to the high 
reactivity of the corresponding aryllithiums. In addition, unlike organoboron, organotin, organozinc and 
organomagnesium compounds, organolithiums can hardly be involved in cross-coupling reactions.2 
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Mixed alkaline organobimetallic mixtures such as those described by Schlosser3 and Lochmann4 
exhibit powerful basic properties that cannot be attained by the homometallic compounds on their own, 
but low chemoselectivities. Organobimetallic mixtures containing only one alkali atom display a large 
panel of reactivities depending on both the non-alkali metal and the groups connected to it. RnMLi–type 
ate compounds, present in stoichiometric5 or catalytic6 amounts in these mixtures, are in general 
supposed to be responsible for the exhibited reactivities (“synergy”). 
In the framework of studies dealing with triazolopyridine systems,7 we have been interested in the 
development of new strategies to functionalize [1,2,3]triazolo[1,5-a]pyridines. Among the methods 
used,8 deprotonative metalation reactions using lithium bases have been developed, and prove efficient 
in the absence of reactive functional groups, provided that very low reaction temperatures are used. 
Herein, we report the first regio-controlled functionalization of [1,2,3]triazolo[1,5-a]pyridines using 
lithium-magnesium and lithium-cadmium organobimetallic bases. 
Results and Discussion 
To develop new deprotonation reactions of [1,2,3]triazolo[1,5-a]pyridines, our approach first 
capitalized on the good reactivity of magnesates. Since 1999, Mulvey has documented the preparation 
of mixed alkali metal-magnesium amides for the site selective deprotonation of benzene,9 toluene,10 
ferrocene,11 ruthenocene,12 osmocene,12 bis(arene)chromium,13 and furan.14 At the same time, we 
studied the deprotonative metalation of pyridines,15 thiophenes,16 oxazoles,17 and furans18 using easily 
available lithium magnesates, the obtained arylmagnesates being either trapped with electrophiles or 
involved in palladium-catalyzed cross-couplings. 
First studies about the lithiation of [1,2,3]triazolo[1,5-a]pyridine (1a) have been reported from 1980, 
and showed butyllithium and lithium diisopropylamide (LiDA) are suitable for a regioselective 
metalation at the 7 position when used in ethereal solvents (the best yields being obtained in 
tetrahydrofuran) provided that the reaction temperature is kept below –40 °C.19 Similar reaction 
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conditions can be used for 3-methyl and 3-phenyl derivatives 1b,c.19 Above this temperature, the 
corresponding 7,7’-dimers form.20 Metalation yields were improved in 1987 by using butyllithium in 
toluene at –40 °C.21 
The deprotonation of [1,2,3]triazolo[1,5-a]pyridine22 (1a) was attempted using 1/3 equiv of lithium 
tributylmagnesate23 (Bu3MgLi) in THF at –10 °C. Addition to the reaction mixture of iodine or 3,4,5-
trimethoxybenzaldehyde after 2 h afforded iodide 2a24 and alcohol 3a, respectively, in moderate yields 
(Table 1, entries 1,2). When treated under the same reaction conditions, 3-methyl25 and 3-phenyl26 
derivatives 1b,c furnished the corresponding iodides 2b,c and alcohols 3b,c in better yields ranging 
from 40 to 75% (Table 1, entries 3-6). Heterocycles being more efficiently deprotonated using 
Bu3MgLi in THF containing TMEDA,
16 a reaction involving 3-methyl-[1,2,3]triazolo[1,5-a]pyridine 
(1b) was attempted with this change, but without improvement. 
TABLE 1. Deprotonation of 1a-c using 
Bu3MgLi (0.4 equiv) Followed by Electrophilic 
Trapping. 
1
2
1) Bu3MgLi
(0.4 equiv)
THF
-10 °C, 2 h
3
N
N N
R
N
N N
R
I
OH
OMe
MeO
MeO
or
2) Electrophile
3) H2O
 
entry substrate product (R) yield (%) 
1 
1a
N
N N
 
2a (H) 34 
2 3a (H) 32 
3 
1b
N
N N
Me
 
2b (Me) 40 (23)a 
4 3b (Me) 61 (60)b 
 5 
5 
1c
N
N N
Ph
 
2c (Ph) 75 
6 3c (Ph) 51 
a Using BuLi, THF, -40 °C.27 b Reaction carried 
out in the presence of TMEDA (0.4 equiv). 
 
In order to synthesize bisheterocycles, cross-coupling reactions between the [1,2,3]triazolo[1,5-
a]pyridines 1a,b magnesates and 2-bromopyridine were attempted under palladium catalysis using 1,1’-
bis(diphenylphosphino)ferrocene (dppf) as ligand,28 but without success. To know if this result could 
be related to the moderate stability of the heterocyclic organomagnesium compounds, we decided to 
involve the corresponding lithium zincates in similar reactions.29 To this purpose, the [1,2,3]triazolo[1,5-
a]pyridines 1a-c were successively treated with butyllithium in tetrahydrofuran at –40 °C for 15 min30 
and zinc chloride (1/3 equivalent) before heating with 2-bromopyridine in the presence of the catalyst. 
This protocol allowed the compounds 4a-c to be obtained in yields ranging from 17% to 60% (Scheme 
1). 
SCHEME 1. Deprotonation of 1a-c Followed 
by Cross-coupling. 
1
4a (R = H): 17%
4b (R = Me): 24%
4c (R = Ph): 60%
1) Bu3MgLi (0.4 equiv)
THF, -10 °C, 2 h
N
N N
R
X
N
2) 2-bromopyridine
PdCl2(dppf) 3mol.%
reflux, 18 h
3) H2O
1) BuLi (1 equiv)
THF, -40 °C, 15 min
2) ZnCl2 (1/3 equiv)
-40 °C to rt, 2 h
3) 2-bromopyridine
PdCl2(dppf) 3mol.%
reflux, 18 h
3) H2O  
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In order to avoid butyllithium which hardly tolerates functional groups, and requires low 
temperatures which can be difficult to realize on an industrial scale, we investigated the deproto-
metalation using a still efficient but more chemoselective ate compound. By combining LiTMP (TMP = 
2,2,6,6-tetramethylpiperidino) with soft organometallic compounds, ate bases such as 
tBu2Zn(TMP)Li,
29f,31 iBu3Al(TMP)Li,
32 (Me3SiCH2)2Mn(TMP)Li·TMEDA
33 and 
MeCu(TMP)(CN)Li2
34 have been prepared and used to generate functionalized aromatic compounds. 
When performed in tetrahydrofuran (THF), the reactions proved to be chemoselective, but require 1 or 
2 equiv of base. We reported very recently a new basic mixture (“TMP-cadmate”), prepared by mixing 
LiTMP (3 equivalents) and CdCl2·TMEDA,
35 that combines both efficiency and chemoselectivity.36 
The method based on the handling of cadmium salts, for which the toxicity is reported,37 was used for 
the functionalization of the sensitive [1,2,3]triazolo[1,5-a]pyridines. 
When substrates 1a and 1c were successively treated by in situ prepared (TMP)3CdLi (0.4 equiv) in 
THF at room temperature for 2 h, and iodine, the expected iodides 2a and 2c were provided in 71 to 
72% yields (Table 2, entries 1 and 3). The iodide 2b was obtained similarly from 1b in 76% yield 
(Table 2, entry 2), but using (TMP)3CdLi (1 equiv). These satisfying results encouraged us to attempt 
the reaction with more elaborated substrates. 
We thus turned to 3-cyano-[1,2,3]triazolo[1,5-a]pyridine38 (1d) for which the deproto-lithiation only 
gives a complex mixture of derivatives.38 When submitted successively to the mixed lithium-cadmium 
base and iodine under the conditions used for 1a-c, the expected iodide 2d39 was isolated in a satisfying 
65% yield (Table 2, entry 4). 3-(2-Pyridyl)-[1,2,3]triazolo[1,5-a]pyridine (1e) and 3-(2-thienyl)-
[1,2,3]triazolo[1,5-a]pyridine (1f) have previously been metalated using LiDA in THF.40 The protocol 
here developed allowed the iodides 2'e and 2f to be obtained (Table 2, entries 5,6). The formation of 
2'e
39 instead of expected 2e can be rationalized as previously reported (Scheme 2).40 
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TABLE 2. Deprotonation of 1a-f using in Situ 
Prepared (TMP)3CdLi (0.4 equiv)
a
 Followed 
by Trapping with I2. 
1 2
1) (TMP)3CdLi
(0.4 equiv)
THF, rt, 2 h
N
N N
R N
N N
RI
2) I2
3) H2O
 
entry 1 R product, yield (%) 
1 1a H 2a, 72 
2 1b Me 2b, 76a (23)b 
3 1c Ph 2c, 71 
4 1d CN 2d, 65 
5 1e 2-pyridyl 2e  2’e, 73 (49)c 
6 1f 2-thienyl 2f, 38 
a 1 equiv of base was used for substrate 1b. b 
Using BuLi, THF, -40 °C.27 c Using LDA, THF, 
-40 °C.40 
SCHEME 2. Isomerization of 7-iodo-3-(2-
pyridyl)-[1,2,3]triazolo[1,5-a]pyridines 2e, 5e 
and 6e. 
2e: R' = R" = H
5e: R' = H, R" = I
6e: R' = R" = I
N N
N
N
I
N
N2
N
I
N
I
N
N
N
R"
R'
R" R"
R' R'
2'e: R' = R" = H
5'e: R' = H, R" = I
6'e: R' = R" = I  
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The basic mixture “TMP-cadmate” being able to dideprotonate substrates such as pyrazine, thiazole, 
N-Boc pyrrole and thiophenes,36 we decided to attempt the access to diiodo derivatives of 
[1,2,3]triazolo[1,5-a]pyridines using 1 equivalent of base. Starting from 1a, the 3,7-diiodo derivative 
5a was isolated in 66% yield (Scheme 3). Unexpectedly, a mixture of the diiodide 5’e and the triiodide 
6'e,41 from which the latter was isolated in 30% yield, was obtained from 1e using the same protocol. 
The iodides 5’e and 6’e probably result from isomerization of the compounds 5e and 6e, as described 
above (Scheme 2). The precursor 5e could be formed by dideprotonation at both 7 (the more activated 
position of [1,2,3]triazolo[1,5-a]pyridine) and 3’ (induced by the neighboring triazole ring) positions.42 
The triiodide 6e could be generated by metalation of 5e during the trapping with iodine (excess of 
base). The formation of the diiodide 5f is less unexpected, and logically results from a dideprotonation 
at the more activated positions of the [1,2,3]triazolo[1,5-a]pyridine and thiophene rings (Scheme 3). 
SCHEME 3. Polydeprotonation of 1a, 1e and 1f using in Situ Prepared (TMP)3CdLi (1 equiv) Followed 
by Trapping with I2. 
1a: R = H
1e: R = 2-pyridyl
1f: R = 2-thienyl
5a: 66%
1) (TMP)3CdLi (1 equiv)
THF, rt, 2 h
N
N N
R N
N N
II
2) I2
3) H2O
5f: 75%
N
N N
I
S I
5'e (R' = H); 6'e (R' = I): 30%
N
N N
I
N
I
R'
 
Even if cross-coupling reactions using cadmium compounds have mostly been described starting 
from organocadmium chlorides,43 reactions from substrates 1a-e were attempted. Preliminary results36 
showing that palladium catalysis using dppf as ligand was appropriate, the metalated intermediates 
were subjected to reaction with 2-bromopyridine at the reflux temperature of THF. Whereas no reaction 
was observed in the presence of an electron-withdrawing group at the 3 position of the 
[1,2,3]triazolo[1,5-a]pyridine ring (substrates 1d,e) under these conditions, the bis(heterocycles) 4a-c 
were isolated in yields ranging from 26 to 67% (Scheme 4). 
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SCHEME 4. Deprotonation of 1a-c using in 
Situ Prepared (TMP)3CdLi (x equiv) Followed 
by Cross-coupling. 
1
4a (R = H): x = 0.4, 26%
4b (R = Me): x = 1, 38%
4c (R = Ph): x = 0.4, 67%
N
N N
R
N
2) 2-bromopyridine
Pd(OAc)2 3 mol.%
dppf 4 mol.%
reflux, 18 h
3) H2O
1) (TMP)3CdLi (x equiv)
THF, rt, 2 h
 
Conclusion 
Modification of organometallic compounds in order to get more chemoselective bases for the 
deprotonation of sensitive substrates is a challenging area. Combining lithium and magnesium 
organometallics in lithium triorganomagnesate (Bu3MgLi) resulted in a good chemoselectivity when 
compared with lithium bases, allowing reactions to be carried out in similar yields at -10 °C instead of -
40 °C using classical lithium bases.19a,21a,27,40,44 Using cadmium instead of magnesium and TMP instead 
of butyl groups afforded an efficient and chemoselective base, able to regioselectively deprotonate 
[1,2,3]triazolo[1,5-a]pyridines substituted or not at the 3 position. Polydeprotonation also proved 
possible in some cases. The heterocyclic lithium cadmates were evidenced using iodine as electrophile. 
Trapping was also attempted using 2-bromopyridine to give the expected coupling products under 
palladium catalysis. Compared to the previously described methods for the synthesis of similar 
bisheterocycles,7d,45 the procedure described here has the advantage of being 'one pot' from the 
corresponding triazolopyridines. 
Due to the toxicity of cadmium compounds,37 we actually try hard to develop basic mixtures 
containing cadmium salts as catalysts. We already observed using anisole as substrate that (TMP)3CdLi 
does not behave as an efficient catalyst when the reaction was performed using a mixture of LiTMP 
(1.5 equivalents) and ZnCl2·TMEDA (0.5 equivalents) in THF at room temperature,
46 but other 
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catalysis experiments are under investigation. Works in order to develop new mixed lithium-metal 
bases of ate type still efficient and chemoselective but less toxic are in parallel under investigation. 
Experimental Section 
General Procedure A (deprotonation using 0.4 equiv Bu3MgLi followed by trapping using I2). 
To a stirred cooled (–10 °C) freshly prepared solution of MgBr247 (0.8 mmol) in THF (5 mL) were 
added BuLi (1.6 M hexanes solution, 2.4 mmol) and, 1 h later, the substrate (2.0 mmol). After 2 h at 
this temperature, a solution of I2 (0.61 g, 2.4 mmol) in THF (5 mL) was added. The mixture was stirred 
overnight before addition of an aq saturated solution of Na2S2O3 (10 mL) and extraction with EtOAc (3 
x 20 mL). The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure. 
General Procedure A’ (deprotonation using 0.4 equiv Bu3MgLi followed by trapping using 
3,4,5-trimethoxybenzaldehyde). To a stirred cooled (–10 °C) freshly prepared solution of MgBr247 
(0.8 mmol) in THF (5 mL) were added BuLi (1.6 M hexanes solution, 2.4 mmol) and, 1 h later, the 
substrate (2.0 mmol). After 2 h at this temperature, 3,4,5-trimethoxybenzaldehyde (0.48 g, 2.4 mmol) 
was added. The mixture was stirred overnight before addition of water (10 mL) and extraction with 
EtOAc (3 x 20 mL). The combined organic layers were dried over MgSO4, filtered and concentrated 
under reduced pressure. 
General Procedure B (deprotonation using 0.4 equiv CdCl2·TMEDA and 1.2 equiv LiTMP 
followed by trapping using I2). To a stirred cooled (0 °C) solution of 2,2,6,6-tetramethylpiperidine 
(0.42 mL, 2.4 mmol) in THF (5 mL) were added BuLi (1.6 M hexanes solution, 2.4 mmol) and, 5 min 
later, CdCl2·TMEDA
35 (0.24 g, 0.8 mmol). The mixture was stirred for 10 min at 0 °C before 
introduction of the substrate (2.0 mmol). After 2 h at room temperature, a solution of I2 (0.61 g, 2.4 
mmol) in THF (5 mL) was added. The mixture was stirred overnight before addition of an aq saturated 
 11 
solution of Na2S2O3 (10 mL) and extraction with EtOAc (3 x 20 mL). The combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure. 
General Procedure C (deprotonation using 1.0 equiv CdCl2·TMEDA and 3.0 equiv LiTMP 
followed by trapping using I2). To a stirred cooled (0 °C) solution of 2,2,6,6-tetramethylpiperidine 
(1.1 mL, 6.0 mmol) in THF (5 mL) were successively added BuLi (1.6 M hexanes solution, 6.0 mmol) 
and, 5 min later, CdCl2·TMEDA
35 (0.60 g, 2.0 mmol). The mixture was stirred for 10 min at 0 °C 
before introduction of the substrate (2.0 mmol). After 2 h at room temperature, a solution of I2 (1.5 g, 
6.0 mmol) in THF (5 mL) was added. The mixture was stirred overnight before addition of an aq 
saturated solution of Na2S2O3 (10 mL) and extraction with EtOAc (3 x 20 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure. 
General Procedure D (deprotonation using 1 equiv BuLi followed by transmetalation using 
ZnCl2 and cross-coupling). To a stirred cooled (–40 °C) solution of the substrate (2.0 mmol) in THF 
(4 mL) were added BuLi (1.6 M hexanes solution, 2.4 mmol) and, 15 min later, a solution of ZnCl2 
(0.12 g, 0.8 mmol) in THF (3 mL). After 2 h at room temperature, the mixture thus obtained was added 
dropwise to a solution of 2-bromopyridine (0.19 mL, 2.0 mmol) and PdCl2(dppf) (49 mg, 60 mol), 
and the resulting mixture was heated at reflux for 18 h before addition of water saturated with NH4Cl 
(0.5 mL) and AcOEt (30 mL). After drying over MgSO4, the organic phase was filtered and 
concentrated under reduced pressure. 
General Procedure E (deprotonation using 0.4 equiv CdCl2·TMEDA and 1.2 equiv LiTMP 
followed by cross-coupling). To a stirred cooled (0 °C) solution of 2,2,6,6-tetramethylpiperidine (0.42 
mL, 2.4 mmol) in THF (5 mL) were added BuLi (1.6 M hexanes solution, 2.4 mmol) and, 5 min later, 
CdCl2·TMEDA
35 (0.24 g, 0.8 mmol). The mixture was stirred for 10 min at 0 °C before introduction of 
the substrate (2.0 mmol). After 2 h at room temperature, the mixture was treated with Pd(OAc)2 (13 
mg, 60 mol), dppf (44 mg, 80 mol) and 2-bromopyridine (0.19 mL, 2.0 mmol). The mixture was 
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heated under reflux for 18 h before addition of water (0.5 mL) and AcOEt (30 mL). After drying over 
MgSO4, the organic phase was filtered and concentrated under reduced pressure. 
General Procedure E’ (deprotonation using 1 equiv CdCl2·TMEDA and 3 equiv LiTMP 
followed by cross-coupling). To a stirred cooled (0 °C) solution of 2,2,6,6-tetramethylpiperidine (1.1 
mL, 6.0 mmol) in THF (5 mL) were added BuLi (1.6 M hexanes solution, 6.0 mmol) and, 5 min later, 
CdCl2·TMEDA
35 (0.60 g, 2.0 mmol). The mixture was stirred for 10 min at 0 °C before introduction of 
the substrate (2.0 mmol). After 2 h at room temperature, the mixture was treated with Pd(OAc)2 (13 
mg, 60 mol), dppf (44 mg, 80 mol) and 2-bromopyridine (0.19 mL, 2.0 mmol). The mixture was 
heated under reflux for 18 h before addition of water (0.5 mL) and AcOEt (30 mL). After drying over 
MgSO4, the organic phase was filtered and concentrated under reduced pressure. 
7-Iodo-[1,2,3]triazolo[1,5-a]pyridine (2a). 2a was obtained according to the general procedure A 
(0.17 g, 34%) or B (0.35 g, 72%), and isolated after purification by flash chromatography on silica gel 
(CH2Cl2/AcOEt: 95/5) as a white powder: mp 148–150 °C; 1H NMR (CDCl3)  6.99 (dd, 1H, J = 8.5 
and 7.2), 7.46 (d, 1H, J = 6.9), 7.72 (d, 1H, J = 8.8), 8.24 (s, 1H); 13C NMR (CDCl3):  86.0 (C), 117.8 
(CH), 126.1 (CH), 127.3 (CH), 127.7 (CH), 134.3 (C); IR (KBr)  1618, 1533, 1480, 1410, 1350, 1308, 
1298, 1261, 1228, 1204, 1144, 1095, 1036, 970, 932, 802, 780, 722, 677, 630 and 580 cm-1. HRMS: 
calcd for C6H4IN3 (M
+•) 244.9450, found 244.9406. Anal. Calcd for C6H4IN3 (245.02): C, 29.41; H, 
1.65; N, 17.15. Found: C, 29.05; H, 1.99; N, 17.13. 
7-Iodo-3-methyl-[1,2,3]triazolo[1,5-a]pyridine (2b). 2b was obtained according to the general 
procedure A (0.21 g, 40%) or C (0.39 g, 76%), and isolated after purification by flash chromatography 
on silica gel (CH2Cl2/AcOEt: 80/20) as a beige powder: mp 135 °C; 
1H NMR (CDCl3)  2.59 (s, 3H), 
6.92 (t, 1H, J = 7.8), 7.41 (d, 1H, J = 6.8), 7.60 (d, 1H, J = 8.7); 13C NMR (CDCl3):  11.0 (CH3), 86.0 
(C), 117.4 (CH), 124.5 (CH), 127.0 (CH), 132.3 (C), 136.6 (C); IR (KBr)  3066, 2962, 2922, 1622, 
1532, 1505, 1458, 1428, 1397, 1335, 1298, 1261, 1225, 1203, 1127, 1103, 1035, 925, 806, 768, 722, 
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672, 610, 551 and 497 cm-1. HRMS: calcd for C7H6IN3 (M
+•) 258.9606, found 258.9586. Anal. Calcd 
for C7H6IN3 (259.05): C, 32.46; H, 2.33; N, 16.22. Found: C, 32.66; H, 2.49; N, 15.82. 
7-Iodo-3-phenyl-[1,2,3]triazolo[1,5-a]pyridine (2c). 2c was obtained according to the general 
procedure A (0.48 g, 75%) or B (0.46 g, 71%), and isolated after purification by flash chromatography 
on silica gel (heptane/CH2Cl2: 50/50) as a yellow powder: mp 139 °C; 
1H NMR (CDCl3)  7.03 (dd, 
1H, J = 8.8 and 7.0), 7.39 (t, 1H, J = 7.4), 7.47-7.52 (m, 3H), 7.91-7.98 (m, 3H); 13C NMR (CDCl3):  
86.6 (C), 118.2 (CH), 126.3 (CH), 126.9 (2CH), 127.4 (CH), 128.2 (CH), 129.1 (2CH), 131.2 (C), 
131.5 (C), 140.0 (C); IR (KBr)  3087, 3052, 1614, 1509, 1484, 1448, 1418, 1345, 1291, 1267, 1215, 
1184, 1134, 1073, 1039, 1007, 929, 804, 789, 767, 729, 696, 688, 610 and 538 cm-1. HRMS: calcd for 
C12H8IN3 (M
+•) 320.9763, found 320.9763. Anal. Calcd for C12H8IN3 (321.12): C, 44.88; H, 2.51; N, 
13.09. Found: C, 44.59; H, 2.56; N, 12.99. 
3-Cyano-7-iodo-[1,2,3]triazolo[1,5-a]pyridine (2d). 2d was obtained according to the general 
procedure B (0.35 g, 65%), and isolated after purification by flash chromatography on silica gel 
(CH2Cl2) as a white powder: mp 202 °C; 
1H NMR ((CD3)2SO)  7.51 (t, 1H, J = 7.8), 7.92 (d, 1H, J = 
6.9), 8.18 (d, 1H, J = 8.6); 1H NMR (CDCl3)  7.26 (dd, 1H, J = 8.8 and 7.2), 7.60 (dd, 1H, J = 7.1 and 
0.9), 7.83 (dd, 1H, J = 8.7 and 0.9); 13C NMR ((CD3)2SO):  91.8 (C), 112.0 (C), 112.6 (C), 116.3 
(CH), 129.1 (CH), 131.6 (CH), 137.0 (C). Anal. Calcd for C7H3IN4 (270.03): C, 31.14; H, 1.12; N, 
20.75. Found: C, 31.20; H, 1.21; N, 20.54. 
3-(6-Iodo-2-pyridyl)-[1,2,3]triazolo[1,5-a]pyridine (2’e).40 2’e was obtained according to the 
general procedure B (0.47 g, 73%), and isolated after purification by flash chromatography on silica gel 
(CH2Cl2/AcOEt: 80/20) as a beige powder: mp 191 °C; 
1H NMR (CDCl3)  7.06 (td, 1H, J = 6.8 and 
0.8), 7.37-7.44 (m, 2H), 7.60 (d, 1H, J = 7.6), 8.27 (d, 1H, J = 7.8), 8.59 (d, 1H, J = 8.9), 8.74 (d, 1H, J 
= 7.0); 13C NMR (CDCl3):  116.2 (CH), 117.4 (C), 119.2 (CH), 121.0 (CH), 125.4 (CH), 127.1 (CH), 
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132.2 (C), 132.8 (CH), 135.9 (C), 138.2 (CH), 153.2 (C). Anal. Calcd for C11H7IN4 (322.10): C, 41.02; 
H, 2.19; N, 17.39. Found: C, 40.98; H, 2.32; N, 17.52. 
7-Iodo-3-(2-thienyl)-[1,2,3]triazolo[1,5-a]pyridine (2f). 2f was obtained according to the general 
procedure B (0.25 g, 38%), and isolated after purification by flash chromatography on silica gel 
(CH2Cl2/AcOEt: 80/20) as a beige powder: mp 134 °C; 
1H NMR (CDCl3)  6.95 (dd, 1H, J = 8.8 and 
7.0), 7.05 (dd, 1H, J = 5.0 and 3.6), 7.28 (dd, 1H, J = 5.0 and 1.0), 7.38 (dd, 1H, J = 6.9 and 0.8), 7.45 
(dd, 1H, J = 3.6 and 1.0), 7.85 (dd, 1H, J = 8.9 and 0.8); 13C NMR (CDCl3):  86.6 (C), 118.1 (CH), 
124.4 (CH), 125.5 (CH), 126.4 (CH), 127.6 (CH), 127.9 (CH), 130.4 (C), 133.3 (C), 135.5 (C). Anal. 
Calcd for C10H6IN3S (327.14): C, 36.71; H, 1.85; N, 12.84; S, 9.80. Found: C, 36.46; H, 1.98; N, 
12.41; S, 10.08. 
([1,2,3]Triazolo[1,5-a]pyrid-7-yl) (3,4,5-trimethoxyphenyl) methanol (3a). 3a was obtained 
according to the general procedure A’ (0.20 g, 32%), and isolated after purification by flash 
chromatography on silica gel (AcOEt/cyclohexane: 80/20) as a yellow powder: mp < 50 °C; 1H NMR 
(CDCl3)  3.72 (s, 9H), 6.48 (s, 1H), 6.74 (s, 2H), 6.83 (d, 1H, J = 7.0), 7.17 (dd, 1H, J = 9.0 and 7.0), 
7.58 (d, 1H, J = 9.0), 7.99 (s, 1H), OH not seen; 13C NMR (CDCl3):  153.6 (2C), 140.8 (C), 138.0 (C), 
135.0 (C), 134.4 (C), 126.3 (CH), 126.1 (CH), 117.2 (CH), 113.3 (CH), 104.5 (2CH), 71.2 (CH), 61.2 
(CH3), 56.4 (2CH3); IR (KBr)  3274, 3007, 2938, 2839, 1638, 1594, 1506, 1463, 1421, 1327, 1234, 
1184, 1127, 1005, 967, 815, 754, 700, 665 and 577 cm-1. HRMS: calcd for C16H17N3O4 (M
+•) 
315.1219, found 315.1225. 
(3-Methyl-[1,2,3]triazolo[1,5-a]pyrid-7-yl) (3,4,5-trimethoxyphenyl) methanol (3b). 3b was 
obtained according to the general procedure A’ (0.40 g, 61%), and isolated after purification by flash 
chromatography on silica gel (AcOEt/cyclohexane: 80/20) as a yellow powder: mp 144–146 °C; 1H 
NMR (CDCl3)  2.62 (s, 3H), 3.82 (s, 9H), 6.48 (s, 1H), 6.72 (d, 1H, J = 7.0), 6.80 (s, 2H), 7.17 (dd, 
1H, J = 9.0 and 6.8), 7.58 (d, 1H, J = 9.0), OH not seen; 13C NMR (CDCl3):  153.8 (2C), 140.1 (C), 
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138.3 (C), 135.4 (C), 134.3 (C), 132.5 (C), 124.6 (CH), 117.0 (CH), 113.6 (CH), 104.5 (2CH), 71.9 
(CH), 61.3 (CH3), 56.5 (2CH3), 10.8 (CH3); IR (KBr)  3468, 2943, 2831, 1639, 1595, 1509, 1450, 
1422, 1332, 1224, 1176, 1129, 1076, 1002, 957, 833, 798, 771, 736, 696, 665, 582, 530 and 492 cm-1. 
HRMS: calcd for C17H19N3O4 (M
+•) 329.1376, found 329.1357. 
(3-Phenyl-[1,2,3]triazolo[1,5-a]pyrid-7-yl) (3,4,5-trimethoxyphenyl) methanol (3c). 3c was 
obtained according to the general procedure A’ (0.40 g, 51%), and isolated after purification by flash 
chromatography on silica gel (AcOEt/cyclohexane: 80/20) as a yellow powder: mp < 50 °C; 1H NMR 
(CDCl3)  3.74 (s, 9H), 4.95 (s, 1H), 6.48 (s, 1H), 6.75 (s, 2H), 6.79 (d, 1H, J = 6.8), 7.20 (dd, 1H, J = 
8.9 and 6.8), 7.30 (m, 1H), 7.40 (m, 2H), 7.84 (m, 3H); 13C NMR (CDCl3):  152.2 (2C), 139.6 (C), 
137.3 (C), 135.8 (C), 133.3 (C), 130.1 (C), 129.9 (C), 128.0 (2CH), 127.1 (CH), 125.7 (2CH), 125.1 
(CH), 116.2 (CH), 112.2 (CH), 103.1 (2CH), 70.0 (CH), 59.8 (CH3), 54.9 (2CH3); IR (KBr)  3370, 
2937, 2836, 1635, 1593, 1547, 1506, 1462, 1421, 1329, 1233, 1184, 1126, 1075, 1004, 959, 832, 799, 
778, 738, 694, 665 and 583 cm-1. HRMS: calcd for C22H21N3O4 (M
+•) 391.1532, found 391.1578. 
3,7-Diiodo-[1,2,3]triazolo[1,5-a]pyridine (5a). 5a was obtained according to the general procedure 
C (0.49 g, 66%), and isolated after purification by flash chromatography on silica gel (heptane/AcOEt: 
50/50) as a beige powder: mp 144 °C; 1H NMR (CDCl3)  7.08 (dd, 1H, J = 8.7 and 6.8), 7.53 (d, 1H, J 
= 5.9), 7.60 (d, 1H, J = 8.8); 13C NMR (CDCl3):  80.9 (C), 86.4 (C), 117.9 (CH), 127.1 (CH), 128.1 
(CH), 136.7 (C); Anal. Calcd for C6H3I2N3 (370.92): C, 19.43; H, 0.82; N, 11.33. Found: C, 19.74; H, 
0.97; N, 11.18. 
3-(5,6-Diiodo-2-pyridyl)-4-iodo-[1,2,3]triazolo[1,5-a]pyridine (6'e). 6'e was obtained according to 
the general procedure C (0.34 g, 30%), and isolated after purification by flash chromatography on silica 
gel (CH2Cl2/AcOEt: 95/5) as a white powder: mp 245 °C; 
1H NMR ((CD3)2SO)  7.03 (t, 1H, J = 7.0), 
7.76 (d, 1H, J = 8.2), 8.00 (dd, 1H, J = 7.0 and 0.65), 8.11 (d, 1H, J = 8.2), 9.23 (dd, 1H, J = 7.0 and 
0.65); 13C NMR ((CD3)2SO):  82.0 (C), 101.7 (C), 118.8 (C), 117.2 (CH), 125.9 (CH), 131.9 (C), 
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136.3 (CH), 137.3 (CH), 139.5 (C), 147.6 (CH), 154.5 (C). Anal. Calcd for C11H5I3N4 (573.90): C, 
23.02; H, 0.88; N, 9.76. Found: C, 23.31; H, 1.11; N, 9.86. 
7-Iodo-3-(5-iodo-2-thienyl)-[1,2,3]triazolo[1,5-a]pyridine (5f). 5f was obtained according to the 
general procedure C (0.68 g, 75%), and isolated after purification by flash chromatography on silica gel 
(CH2Cl2) as a yellow powder: mp 201 °C; 
1H NMR (CDCl3)  7.09 (dd, 1H, J = 9.0 and 6.8), 7.22-7.32 
(m, 2H), 7.53 (dd, 1H, J = 6.9 and 0.9), 7.92 (dd, 1H, J = 9.0 and 1.0); 1H NMR ((CD3)2SO)  7.25 (t, 
1H, J = 7.9), 7.36-7.41 (m, 2H), 7.75 (d, 1H, J = 6.9), 8.21 (d, 1H, J = 8.8); 13C NMR ((CD3)2SO):  
76.1 (C), 90.0 (C), 117.7 (CH), 125.8 (CH), 127.8 (CH), 127.9 (CH), 129.5 (C), 133.4 (C), 137.9 (CH), 
138.8 (C). Anal. Calcd for C10H5I2N3S (453.04): C, 26.51; H, 1.11; N, 9.28; S, 7.08. Found: C, 26.77; 
H, 1.17; N, 9.27; S, 7.27. 
7-(2-Pyridyl)-[1,2,3]triazolo[1,5-a]pyridine (4a). 4a was obtained according to the general 
procedure D (67 mg, 17%) or E (0.10 g, 26%), and isolated after purification by flash chromatography 
on silica gel (CH2Cl2/AcOEt: 80/20) as a white powder: mp 94 °C; 
1H NMR (CDCl3)  7.39-7.45 (m, 
2H), 7.82 (dd, 1H, J = 8.7 and 1.0), 7.90-7.96 (m, 2H), 8.21 (s, 1H), 8.79-8.80 (m, 1H), 9.00 (d, 1H, J = 
8.2); 13C NMR (CDCl3):  116.7 (CH), 118.0 (CH), 124.5 (CH), 125.3 (CH), 125.7 (CH), 126.2 (CH), 
135.1 (C), 136.7 (C), 136.9 (CH), 149.2 (C), 149.9 (CH); IR (KBr)  3134, 3059, 2926, 2862, 1634, 
1584, 1570, 1510, 1466, 1436, 1417, 1369, 1324, 1262, 1206, 1153, 1102, 1046, 995, 976, 953, 902, 
837, 769, 732, 698, 678, 627, 612, 576 and 496 cm-1. HRMS: calcd for C11H8N4 (M
+•) 196.0749, found 
196.0732. Anal. Calcd for C11H8N4 (196.21): C, 67.34; H, 4.11; N, 28.55. Found: C, 67.06; H, 4.29; N, 
28.29. 
3-Methyl-7-(2-pyridyl)-[1,2,3]triazolo[1,5-a]pyridine (4b). 4b was obtained according to the 
general procedure D (0.10 g, 24%) or E’ (0.16 g, 38%), and isolated after purification by flash 
chromatography on silica gel (CH2Cl2/AcOEt: 80/20) as a white powder: mp 68 °C; 
1H NMR (CDCl3) 
 2.68 (s, 3H), 7.32 (m, 2H), 7.70 (dd, 1H, J = 8.7 and 1.0), 7.89-7.95 (m, 2H), 8.78 (d, 1H, J = 4.5), 
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9.02 (d, 1H, J = 8.1); 13C NMR (CDCl3):  10.6 (CH3), 116.6 (CH), 117.6 (CH), 124.2 (CH), 124.4 
(CH), 125.2 (CH), 133.1 (C), 134.8 (C), 136.5 (C), 136.9 (CH), 149.4 (C), 149.8 (CH); IR (KBr)  
3053, 3010, 2926, 2852, 1630, 1583, 1533, 1467, 1429, 1380, 1343, 1315, 1203, 1155, 1125, 1089, 
1045, 990, 947, 808, 777, 731, 696, 676, 616 and 568 cm-1. HRMS: calcd for C12H10N4 (M
+•) 
210.0905, found 210.0869. Anal. Calcd for C12H10N4 (210.23): C, 68.56; H, 4.79; N, 26.65. Found: C, 
68.31; H, 4.78; N, 26.53. 
3-Phenyl-7-(2-pyridyl)-[1,2,3]triazolo[1,5-a]pyridine (4c). 4c was obtained according to the 
general procedure D (0.33 g, 60%) or E (0.36 g, 67%), and isolated after purification by flash 
chromatography on silica gel (heptane/AcOEt: 50/50) and recrystallization from heptane/Et2O (30/70) 
as a yellow powder: mp 95–97 °C; 1H NMR (CDCl3)  7.39-7.57 (m, 5H), 7.91-8.02 (m, 4H), 8.09 (dd, 
1H, J = 8.9 and 1.0), 8.80 (ddd, J = 3.8, 1.6 and 0.8), 9.05 (d, 1H, J = 8.1); 13C NMR (CDCl3):  117.0 
(CH), 118.4 (CH), 124.5 (CH), 125.4 (CH), 126.1 (CH), 127.0 (2CH), 128.1 (CH), 129.1 (2CH), 131.6 
(C), 131.9 (C), 136.8 (CH), 137.0 (C), 138.3 (C), 149.2 (C), 149.9 (CH); IR (KBr)  3064, 2989, 1630, 
1605, 1571, 1532, 1496, 1466, 1427, 1349, 1318, 1299, 1265, 1220, 1159, 1139, 1117, 1072, 1051, 
1008, 990, 916, 802, 782, 748, 736, 696, 616, 599 and 564 cm-1. HRMS: calcd for C17H12N4 (M
+•) 
272.1062, found 272.1026. Anal. Calcd for C17H12N4 (272.30): C, 74.98; H, 4.44; N, 20.58. Found: C, 
74.71; H, 4.39; N, 20.33. 
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